Literature DB >> 1974831

The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation.

A N Akbar1, P L Amlot, A Timms, G Lombardi, R Lechler, G Janossy.   

Abstract

In normal individuals, 80 +/- 5% of circulating CD8+ T cells express CD45RA, and 20 +/- 7% of these cells express CD45R0 antigens. After activation, CD8+ cells expressing CD45RA decrease to 56-67% while those expressing CD45R0 increase to 38-67%. Although precursors of alloantigen-specific cytotoxic T cells were found in both CD8+, CD45RA+ and CD8+, CD45R0+ subsets, the specific effector cells were exclusively CD8+, CD45R0. Allospecific cytotoxic CD8+ clones were also entirely CD45R0+. A lectin-dependent cytotoxic (LDC) assay unmasked a hierarchy of killing after alloactivation which was CD8+, CD45R0+ greater than CD8+, CD45RA+ greater than CD4+, CD45R0+ greater than CD4+, CD45RA+. The phenotype of CD8+ T cells in rejecting kidneys was similar to in vitro alloantigen-activated CD8+, CD45R0+ cells and cytotoxic CD8+ clones. Firstly there was an increase in the relative proportions of CD45R0+ (60 +/- 8%) and a decrease in CD45RA+ (35 +/- 10%) CD8+ cells relative to circulating CD8+ subsets. In the rejecting grafts, 34 +/- 9% of the CD8+ cells were also DR+ indicative of recent activation. Furthermore, 16% (range 4-35%) of rejecting CD8+ cells were Ki67+ suggesting that these cells were proliferating. Finally, 17% (range 4-53%) of T cells in rejecting kidneys simultaneously expressed both CD45RA and CD45R0 markers. These results show that in vitro alloantigen-activated CD8+, CD45R0+ cells represent a primed/memory cytotoxic population. In addition, they provide indirect evidence that a proportion of CD8+ cells in rejecting kidneys were actively switching from a naive to a memory phenotype in vivo in a manner analogous to that in vitro.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974831      PMCID: PMC1535035          DOI: 10.1111/j.1365-2249.1990.tb03322.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation.

Authors:  M E Sanders; M W Makgoba; C H June; H A Young; S Shaw
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

2.  Cellular events during memory T-cell activation in vitro: the UCHL1 (180,000 MW) determinant is newly synthesized after mitosis.

Authors:  A N Akbar; A Timms; G Janossy
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

3.  Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation.

Authors:  M Merkenschlager; L Terry; R Edwards; P C Beverley
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

4.  Differential activation requirements for virgin and memory T cells.

Authors:  J A Byrne; J L Butler; M D Cooper
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

5.  The functionally distinct subpopulations of human CD4+ helper/inducer T lymphocytes defined by anti-CD45R antibodies derive sequentially from a differentiation pathway that is regulated by activation-dependent post-thymic differentiation.

Authors:  L T Clement; N Yamashita; A M Martin
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

6.  Co-recognition of endogenous antigens with HLA-DR1 by alloreactive human T cell clones.

Authors:  G Lombardi; S Sidhu; J R Lamb; J R Batchelor; R I Lechler
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

7.  The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45.

Authors:  L A Terry; M H Brown; P C Beverley
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

8.  Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones.

Authors:  M Salmon; G D Kitas; P A Bacon
Journal:  J Immunol       Date:  1989-08-01       Impact factor: 5.422

9.  The MRC OX-22- CD4+ T cells that help B cells in secondary immune responses derive from naive precursors with the MRC OX-22+ CD4+ phenotype.

Authors:  F Powrie; D Mason
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  In vivo expression of perforin by CD8+ lymphocytes during an acute viral infection.

Authors:  L H Young; L S Klavinskis; M B Oldstone; J D Young
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  13 in total

1.  Differentiation of human alloreactive CD8(+) T cells in vitro.

Authors:  Rob J Rentenaar; Jelle L G Vosters; Frank N J van Diepen; Ester B M Remmerswaal; René A W van Lier; Ineke J M ten Berge
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration.

Authors:  N J Borthwick; A N Akbar; L P MacCormac; M Lowdell; J L Craigen; I Hassan; J E Grundy; M Salmon; K L Yong
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

Review 3.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

4.  Differential infiltration by CD45RO and CD45RA subsets of T cells associated with human heart allograft rejection.

Authors:  S Ibrahim; D V Dawson; P Van Trigt; F Sanfilippo
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

5.  Memory T Cells in Transplantation.

Authors:  Charles A Su; Robert L Fairchild
Journal:  Curr Transplant Rep       Date:  2014-09-01

6.  CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.

Authors:  R Gorla; P Airò; A Malagoli; G Carella; E Prati; D Brugnoni; F Franceschini; R Cattaneo
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

7.  IL-2 infusion abrogates humoral immune responses in humans.

Authors:  D J Gottlieb; H G Prentice; H E Heslop; C Bello; M K Brenner
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

8.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

9.  The roles of CD8 central and effector memory T-cell subsets in allograft rejection.

Authors:  M H Oberbarnscheidt; Y-H Ng; G Chalasani
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

10.  CD8+ T-cell subsets defined by expression of CD45 isoforms differ in their capacity to produce IL-2, IFN-gamma and TNF-beta.

Authors:  D Adamthwaite; M A Cooley
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.